Clinical trial • Phase III • Cardiology
MK-3214 for Hypercholesterolemia
Phase III trial of MK-3214 for Hypercholesterolemia. 32 participants.
Overview
- Trial Therapeutic Area
- Cardiology
- Trial Disease
- Hypercholesterolemia
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 26-01-2026
- First CTIS Authorization Date
- 06-03-2026
Trial design
Phase III trial across 1 site in Belgium.
- Target Sample Size
- 32
Recruitment
- Planned Sample Size
- 32
- Recruitment Window Months
- 2
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 32
Belgium
- Earliest CTIS Part Ii Submission Date
- 18-02-2026
- Latest Decision Or Authorization Date
- 06-03-2026
- Processing Time Days
- 16
- Number Of Sites
- 1
- Number Of Participants
- 32
Sites
- Site Name
- Universitair Ziekenhuis Gent
- Department Name
- DRUG
- Principal Investigator Name
- Griet Van Lancker
- Principal Investigator Email
- Griet.vanlancker@uzgent.be
- Contact Person Name
- Griet Van Lancker
- Contact Person Email
- Griet.vanlancker@uzgent.be
Sponsor
Primary sponsor
- Full Name
- Merck Sharp & Dohme LLC
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- MK-3214
Related trials
Other published trials that may interest you.